This study is in progress, not accepting new patients
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
Summary
- Eligibility
- for people ages 18-130 (full criteria)
- Location
- at Los Angeles, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Alexandra Drakaki
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCLA
- Alexandra Drakaki
HS Associate Clinical Professor, Medicine. Authored (or co-authored) 103 research publications
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- AstraZeneca
- ID
- NCT03732677
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- About 1063 people participating
- Last Updated